Table 1.
First line maintenance treatment trials with PARP inhibitor
| Trial name | Study group | Treatment arms | Median PFS for control group in months | Median PFS for treatment group in months (HR) |
|---|---|---|---|---|
| SOLO1 | Stage III-IV high grade EOC with BRCA 1/2 mutation |
Arm 1: Olaparib 300mg BD Arm 2: Placebo |
13.8 | 49.9 (0.30) |
| PRIMA | Stage III-IV high grade EOC |
Arm 1: Niraparib 300/200 mg OD Arm 2: Placebo |
BRCAmut: 10.9 HRD: 8.2 HRP: 5.4 |
BRCAmut: 22.1 (0.40) HRD: 19.6 (0.50) HRP: 8.1 (0.68) |
| VELIA | Stage III-IV high grade serous EOC |
Arm 1: Chemotherapy+ placebo followed with placebo maintenance Arm 2: Chemotherapy+ Veliparib followed by placebo maintenance Arm 3: Chemotherapy +Veliparib 150 mg, followed by Veliparib maintenance 400 mg BD |
BRCAmut: 22.0 HRD: 30.5 Intention to treat: 7.3 |
BRCAmut: 37.7 (0.44) HRD: 31.9 (0.57) Intention to treat: 23.5 (0.68) |
| PAOLA1 | Stage III-IV high grade EOC |
Arm 1: Olaparib 300mg BD +Bevacizumab 15mg/kg q 3 weeks Arm 2: Placebo + Bevacizumab 15mg/kg q 3 weeks |
Tumour BRCAmut: 21.7 Tumour BRCA -ve: 16.0 HRD (+ BRCAmut): 17.7 HRD (without BRCA): 16.6 HRP/unknown: 16.0 |
Tumour BRCAmut: 37.2 (0.31) Tumour BRCA -ve: 18.9 (0.71) HRD (+ BRCAmut): 37.2 (0.33) HRD (without BRCA): 28.1 (0.43) HRP/unknown: 16.9 (0.92) |
EOC, epithelial ovarian cancer; PFS, progression-free survival; HR, hazard ratio; HRD, homologous recombination deficient; HRP, homologous recombination proficient